Expression level of EGFR and MET receptors regulates invasiveness of melanoma cells.

Epidermal and hepatocyte growth factors can stimulate invasive abilities of melanoma cells, while treatment with combination of their receptors' (EGFR and MET, respectively) inhibitors reduces viability of these cells, as we have previously shown. Proposed therapy has potential; however, used drugs block more than one goal effectively, what raises the question about the real target of analysed inhibitors. For this reason, we analysed direct involvement of these receptors in the invasion of melanoma cells inducing EGFR and MET up- and down-regulations in examined cells.

Combination of EGFR Inhibitor Lapatinib and MET Inhibitor Foretinib Inhibits Migration of Triple Negative Breast Cancer Cell Lines.

Triple-negative breast cancer (TNBC) is the most challenging subtype to treat due to the lack of estrogen receptor, progesterone receptor, and HER2 expression, which excludes the usage of directed targeted therapy against them. Promising therapeutic targets are the hepatocyte growth factor receptor (MET) and epidermal growth factor receptor (EGFR), which expression is frequently elevated in TNBC. Inhibitors of these receptors used as monotherapy are often ineffective.

Actin content and polymerization in tumour, liver and serum of the hepatoma Morris 5123 tumour bearing rats.

Monomeric G-actin, total actin and filamentous F-actin were examined during the growth of experimental tumour hepatoma Morris 5123. Actin was measured by the inhibition of the standard DNase I from bovine pancreas. A remarkable increase in total actin, and F-actin content, as well as in the state of actin polymerization (measured by the F:G actin ratio) was shown in the cytosol of the tumour cells in the second week of the tumour growth, followed by a rapid decrease in the third week.